Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 11:15:1639-1644.
doi: 10.2147/JAA.S375134. eCollection 2022.

Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma

Asif H Khan #  1 , Cori Gray #  2 , Laurent Eckert  1 , Caroline Amand  1 , Jaman Maroni  3 , Zhixiao Wang  3 , Bethan Jones  4 , Thomas Berni  4 , Christopher Ll Morgan  4 , Paul J Rowe  5
Affiliations

Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma

Asif H Khan et al. J Asthma Allergy. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Khan AH, Gray C, Eckert L, Amand C and Rowe PJ are employees of Sanofi, may hold stock and/or stock options in the company. Maroni J and Wang Z are employees of Regeneron Pharmaceuticals Inc, may hold stock and/or stock options in the company. Jones B, Berni T and Morgan CL are employees of Pharmatelligence, which was funded by Sanofi to conduct the study. The authors report no other conflicts of interest.

Figures

Figure 1
Figure 1
Rates of severe asthma exacerbations over 12 months in patients with moderate-to-severe asthma, categorized by baseline FEV1pp values. †Group 1, N = 1106; Group 2, N = 644; Group 3, N = 115. ‡Group 1, N = 302; Group 2, N = 209; Group 3, N = 43.
Figure 2
Figure 2
(A) Incident rate ratio over 12 months and (B) hazard ratio for risk of severe exacerbation over 36 months in patients with moderate-to-severe asthma, categorized by baseline FEV1pp values. P-value for Group 2 and 3 were evaluated versus Group 1. Adjusted for age at the index date, smoking status, BMI, gender, rhinitis, chronic sinusitis, nasal polyps, atopic dermatitis, diabetes, anaphylaxis, ischemic heart disease, heart failure, food allergy, anxiety, depression, and psoriasis. Patients without a baseline % predicted FEV1 measurement were included in the analysis as a categorical variable.
See this image and copyright information in PMC

References

    1. Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. Available from: http://www.ginasthma.org/. Accessed February 22, 2022.
    1. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005;171(2):109–114. doi:10.1164/rccm.200402-230OC - DOI - PubMed
    1. Krings JG, Goss CW, Lew D, et al. Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: results from SARP-3. J Allergy Clin Immunol. 2021;148(3):752–762. doi:10.1016/j.jaci.2021.01.029 - DOI - PMC - PubMed
    1. Matsunaga K, Hirano T, Oka A, et al. Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations. J Allergy Clin Immunol Pract. 2015;3(5):759–764 e1. doi:10.1016/j.jaip.2015.05.005 - DOI - PubMed
    1. Tupper OD, Ulrik CS. Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma. Respir Res. 2021;22(1):269. doi:10.1186/s12931-021-01864-z - DOI - PMC - PubMed